Shanghai Securities News · China Securities Network: After the herpes zoster mRNA vaccine and the freeze-dried varicella inactivated vaccine, Zhifei Biologics has approved another herpes vaccine for clinical trials. The company announced on November 19 evening that recently, its wholly-owned subsidiary Anhui Zhifei Longkom Bio-Pharmaceutical Co., Ltd. developed the recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cells) has received the drug clinical trial application acceptance notice from the National Medical Products Administration (Acceptance Number: CXSL2500978). Within 60 days from the acceptance date, if no negative or questioning opinions are received from the Drug Evaluation Center, Zhifei Longkom can carry out clinical trials according to the submitted plan.

According to the data, herpes zoster is a common infectious skin disease caused by the reactivation of the varicella-zoster virus that has been dormant in the posterior root ganglia or cranial ganglia of the spinal cord. Vaccination is the most effective and feasible means of preventing herpes zoster and post-herpetic neuralgia. The recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cells) developed by Zhifeng Longkom is used to prevent diseases caused by herpes zoster infection. As of now, after checking the official website of the National Medical Products Administration, two herpes zoster vaccines have been approved for commercial use in China.

According to Zhifei Biological, the company's recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cells) uses an independently developed new adjuvant, which can simultaneously stimulate both cellular and humoral immune responses. The immune response is more comprehensive, and it is expected to enhance the protective effect of the vaccine. The clinical trial application for this vaccine has been accepted, which is an application of the company's new adjuvant technology platform, focusing on innovative technologies and strengthening core research efforts. If this project progresses smoothly, it will further enrich the company's adult vaccine varieties, improve the company's product layout, and strengthen the company's market position.

At the same time, in order to enhance the efficiency of R&D innovation and reduce R&D risks, the company has adopted multiple technical paths such as recombinant protein technology (innovative adjuvants) and mRNA to develop varicella-zoster virus vaccines. The company will comprehensively consider multiple factors including preclinical research data, and select the best and most opportune time to conduct clinical trials for the ongoing varicella-zoster virus vaccine projects. This will deepen the company's advanced technology reserves and lay a solid foundation for its long-term sustainable development.

https://finance.eastmoney.com/a/202511193568983732.html